Cargando…
Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
PURPOSE: To assess a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration (FDA) results and published literature. PATIENTS AND METHODS: Forty-eight eyes (29 patients) with mean pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607143/ https://www.ncbi.nlm.nih.gov/pubmed/33154614 http://dx.doi.org/10.2147/OPTH.S276899 |
_version_ | 1783604585976299520 |
---|---|
author | Moshirfar, Majid Thomson, Andrew C West, William B Hall, MacGregor N McCabe, Shannon E Thomson, Robert J Ronquillo, Yasmyne C Hoopes, Phillip C |
author_facet | Moshirfar, Majid Thomson, Andrew C West, William B Hall, MacGregor N McCabe, Shannon E Thomson, Robert J Ronquillo, Yasmyne C Hoopes, Phillip C |
author_sort | Moshirfar, Majid |
collection | PubMed |
description | PURPOSE: To assess a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration (FDA) results and published literature. PATIENTS AND METHODS: Forty-eight eyes (29 patients) with mean preoperative sphere of −5.11 ± 1.31 diopters (D) and cylinder of −1.12 ± 0.60 D underwent SMILE. Visual acuity, refractive, and vector analysis outcomes as well as subjective measures were reported at three and twelve months postoperatively and compared with FDA results and the published literature between 2014 and 2020 involving treatment of patients with mean cylinders of >−0.50 to ≤−3.00 D. RESULTS: At three and twelve months, 43 and 32 eyes were evaluated, respectively. At twelve months, mean cylinder power was reduced to −0.38 ± 0.38 D with 78.1% achieving ≤±0.50 D. Uncorrected distance visual acuity (UDVA) ≥20/20 was achieved in 77.4% of eyes by twelve months with 100% achieving ≥20/30 UDVA. No loss of corrected distance visual acuity was observed in eyes seen at twelve months. Correction index (CI) at twelve months was 0.90 indicating overall undercorrection of 10%. Twelve-month CI was 0.96, 0.90, and 0.83 in eyes with preoperative cylinders of <−1.00 D, ≥−1.00 to <−2.00 D, and ≥−2.00 D, respectively. Mean angle of error was −1.58 ± 11.61° ranging from −24.22° to 37.75°. CONCLUSION: We found SMILE to be an effective and safe means of achieving spectacle independence and improving visual acuity in patients with myopic astigmatism. SMILE has the potential for improved clinical outcomes with better nomogram guidance and advancements in technique. However, surgeons must be aware of the potential for undercorrection in with-the-rule astigmatism and at higher preoperative cylinders and as well as the potential for overcorrection in against-the-rule and lower preoperative cylinder astigmatism. |
format | Online Article Text |
id | pubmed-7607143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-76071432020-11-04 Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature Moshirfar, Majid Thomson, Andrew C West, William B Hall, MacGregor N McCabe, Shannon E Thomson, Robert J Ronquillo, Yasmyne C Hoopes, Phillip C Clin Ophthalmol Original Research PURPOSE: To assess a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration (FDA) results and published literature. PATIENTS AND METHODS: Forty-eight eyes (29 patients) with mean preoperative sphere of −5.11 ± 1.31 diopters (D) and cylinder of −1.12 ± 0.60 D underwent SMILE. Visual acuity, refractive, and vector analysis outcomes as well as subjective measures were reported at three and twelve months postoperatively and compared with FDA results and the published literature between 2014 and 2020 involving treatment of patients with mean cylinders of >−0.50 to ≤−3.00 D. RESULTS: At three and twelve months, 43 and 32 eyes were evaluated, respectively. At twelve months, mean cylinder power was reduced to −0.38 ± 0.38 D with 78.1% achieving ≤±0.50 D. Uncorrected distance visual acuity (UDVA) ≥20/20 was achieved in 77.4% of eyes by twelve months with 100% achieving ≥20/30 UDVA. No loss of corrected distance visual acuity was observed in eyes seen at twelve months. Correction index (CI) at twelve months was 0.90 indicating overall undercorrection of 10%. Twelve-month CI was 0.96, 0.90, and 0.83 in eyes with preoperative cylinders of <−1.00 D, ≥−1.00 to <−2.00 D, and ≥−2.00 D, respectively. Mean angle of error was −1.58 ± 11.61° ranging from −24.22° to 37.75°. CONCLUSION: We found SMILE to be an effective and safe means of achieving spectacle independence and improving visual acuity in patients with myopic astigmatism. SMILE has the potential for improved clinical outcomes with better nomogram guidance and advancements in technique. However, surgeons must be aware of the potential for undercorrection in with-the-rule astigmatism and at higher preoperative cylinders and as well as the potential for overcorrection in against-the-rule and lower preoperative cylinder astigmatism. Dove 2020-10-29 /pmc/articles/PMC7607143/ /pubmed/33154614 http://dx.doi.org/10.2147/OPTH.S276899 Text en © 2020 Moshirfar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Moshirfar, Majid Thomson, Andrew C West, William B Hall, MacGregor N McCabe, Shannon E Thomson, Robert J Ronquillo, Yasmyne C Hoopes, Phillip C Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature |
title | Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature |
title_full | Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature |
title_fullStr | Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature |
title_full_unstemmed | Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature |
title_short | Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature |
title_sort | initial single-site experience using smile for the treatment of astigmatism in myopic eyes and comparison of astigmatic outcomes with existing literature |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607143/ https://www.ncbi.nlm.nih.gov/pubmed/33154614 http://dx.doi.org/10.2147/OPTH.S276899 |
work_keys_str_mv | AT moshirfarmajid initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT thomsonandrewc initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT westwilliamb initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT hallmacgregorn initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT mccabeshannone initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT thomsonrobertj initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT ronquilloyasmynec initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature AT hoopesphillipc initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature |